<DOC>
	<DOCNO>NCT01291615</DOCNO>
	<brief_summary>To decide maximum tolerate dose and/or recommend dose Gemcitabine S-1 adjuvant therapy hemihepatectomy</brief_summary>
	<brief_title>Phase I Study Gemcitabine S-1 Adjuvant Therapy After Hemihepatectomy Biliary Tract Cancer</brief_title>
	<detailed_description>There standard adjuvant therapy liver hemi-hepatectomy due bile duct cancer , high surgical morbidity ratio high adverse event ratio adjuvant therapy . For example , preliminary result show regular gemcitabine administration ( 1000mg/m2 , day1 , 8 , 15 every 4 week ) hemihepatectomy toxic induce severe leukocytopenia and/or thrombocytopenia . Herein , plan study decide safety adjuvant protocol ( recommend dose ) gemcitabine S-1 hemihepatectomy use continual reassessment method analysis . In study , decide tolerable ratio dose-limiting toxicity would less 10 % .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Biliary tract cancer ( &gt; = UICC Stage IB ) 2 . R0 R1 resection due biliary tract cancer ( BTC ) 3 . ECOG performance status must 0 1 4 . The patient underwent treatment surgery BTC 5 . Neutrophil must 1500/μl , platelet must 100,000/μl , AST ALT must less five time normal limit , total bilirubin must less three time normal limit , creatinin must less 1.2 mg/dl . 6 . The patient intake drug per o . 7 . From 4 12 week surgery 8 . Written inform consent 1 . Existence active double cancer 2 . The patient suffer severe drug allergy 3 . Sever complication ( interstitial pneumonia , heart failure , renal failure , liver failure , ileus , incontrollable diabetes mellitus , ) 4 . Any active infection exist . 5 . Pregnancy 6 . Severe mental disorder 7 . Others</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>